Michael Amoroso - 17 Feb 2026 Form 4 Insider Report for PRECISION BIOSCIENCES INC (DTIL)

Reporting relationship: President and CEO, Director
Issuer ticker: DTIL
Reported as of: 17 Feb 2026
Net transaction value: -$78,947
SEC form: 4
Accepted by SEC: 19 Feb 2026, 16:31:08 UTC
Prior SEC filing: 27 Jan 2026
Next SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Dario Scimeca, Attorney-in-Fact for Michael Amoroso

Key filing fact

Michael Amoroso filed Form 4 for PRECISION BIOSCIENCES INC (DTIL) on 19 Feb 2026.

Key facts

This page summarizes Michael Amoroso's Form 4 filing for PRECISION BIOSCIENCES INC (DTIL).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 Feb 2026, 16:31.

Change

Previous filing in this sequence was filed on 27 Jan 2026.
Current net transaction value: -$78,947.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001830874 Primary reporting owner

Amoroso Michael

Relationship: President and CEO, Director
Address: C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM
Signature: /s/ Dario Scimeca, Attorney-in-Fact for Michael Amoroso
Signature date: 19 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DTIL transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +67,797
Change %: +35%
Price: $0.000000
Shares after: 263,951
Date: 17 Feb 2026
Ownership: Direct
Footnotes: F1, F2

DTIL transaction

Common Stock

Sale

Transaction value: $78,947
Shares: -20,559
Change %: -7.8%
Price: $3.84
Shares after: 243,392
Date: 18 Feb 2026
Ownership: Direct
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DTIL transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -67,797
Change %: -33%
Price: $0.000000
Shares after: 135,593
Date: 17 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 67,797
Exercise price
Footnotes: F2, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Represents the vesting of Restricted Stock Units ("RSUs") on February 17, 2026.

Footnote F2

Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F3

The sales were effected pursuant to a Rule 10b5-1 plan adopted on August 2, 2024. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.

Footnote F4

RSUs vests in three substantially equal annual installments beginning on February 17, 2026, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.